| Record ID | marc_columbia/Columbia-extract-20221130-031.mrc:328556180:1547 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-031.mrc:328556180:1547?format=raw |
LEADER: 01547cam a2200349Ii 4500
001 15211588
005 20210120110032.0
008 170126s2016 xxua b 000 0 eng d
035 $a(OCoLC)ocn970347311
040 $aMYG$beng$cMYG$erda$dOCLCF
020 $a9780998407500
020 $a099840750X
035 $a(OCoLC)970347311
050 14 $aTP248.2$b.D38 2016
049 $aZCUA
100 1 $aDavid, Frank S.,$eauthor.
245 14 $aThe Pharmagellan guide to biotech forecasting and valuation /$cFrank S. David, Seth Robey, Andrew Matthews.
246 10 $aBiotech forecasting and valuation
250 $aFirst edition
264 1 $a[United States] :$bPharmagellan,$c[2016]
264 4 $c©2016
300 $axi, 124 pages :$billustrations ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references.
505 0 $aPreparing to build a biotech financial model -- Income. Addressable patient population -- Adherence and compliance -- Pricing -- Market share -- Launch curves -- Loss of exclusivity -- Expenses. Costs of goods sold -- Sales, general, and administrative -- Sales force -- Marketing -- R&D -- Regulatory -- Valuation. R&D and regulatory probability of success -- Discount rate.
650 0 $aBiotechnology$xEconomic aspects.
650 7 $aBiotechnology$xEconomic aspects.$2fast$0(OCoLC)fst00832738
700 1 $aRobey, Seth,$eauthor.
700 1 $aMatthews, Andrew,$eauthor.
852 00 $boff,bus$hTP248.2$i.D38 2016g